Updates from the SECURE-IBD* registry reveal that treatment with thiopurine, either alone or in combination with tumour necrosis factor inhibitors (TNFis), for inflammatory bowel disease (IBD) was associated with a greater risk of severe COVID-19 compared with TNFis monotherapy.
Administering benzodiazepines during an acute coronary syndrome (ACS) may spell trouble for patients, with a recent study showing that despite rapidly relieving anxiety, the drug can also contribute to increased risk of post-traumatic stress disorder (PTSD) symptoms.
The efficacy and safety of long-term tildrakizumab are comparable and maintained without evidence of reduced durability of response through 148 weeks of treatment in patients with and without metabolic syndrome (MetS), results from two phase III trials have shown.
Treatment with dulaglutide in type 2 diabetes (T2D) patients with inadequate response to metformin yields meaningful dose-related reductions in blood glucose and body weight without compromising safety, as shown in a study.
Treatment with ultra-short-acting β-blockers, such as esmolol and landiolol, in sepsis and septic shock patients with persistent tachycardia leads to a significantly lower mortality at 28 days despite initial resuscitation, according to the results of a systematic review and meta-analysis.
Hyperkalaemia (HK) occurrence and recurrence are frequent in advanced CKD*, creating a perfect storm for cardiovascular events and death, says Professor Juan-Jesus Carrero from the Karolinska Institute, Solna, Sweden, at ERA-EDTA 2020. Given these risks, acutely elevated potassium (K+) should merit clinical attention.